Baxter International Inc.

Baxter Healthcare Sa

Baxalta Gmbh

New York Blood Center, Inc.

Cytokine Pharmasciences, Inc.

Lin Leng

Richard J Bucala

Christine N Metz

Alex Zhu

Jack Goldstein

Seamas Donnelly

Robert Mitchell

Methods and compositions for using the MHC class II invariant chain polypeptide, Ii (also known as CD74), as a receptor for macrophage migration inhibitory factor (MIF), are disclosed. These include methods and compositions for using this receptor, as well as agonists and antagonists of MIF which bind to this receptor, or which otherwise modulate the interaction of MIF with CD74 or the consequences of such interaction, in treatment of conditions characterized by locally or systemically altered MIF levels, particularly inflammatory conditions and cancer.

Method of inhibiting binding or activity of MIF by administering a MIF antagonist

MIF antagonists

Method for screening for compounds using MHC class II invariant chain polypeptide and macrophage migration inhibitory factor

The present invention relates to purified and isolated nucleic acid encoding the endo-.beta.-galactosidase from Flavobacterium keratolyticus (referred to as 'ENDO-A'), and to purified ENDO-A protein. The endo-.beta.-galactosidase of the invention may be used in a process which enzymatically de-antigenizes human erythrocytes bearing A.sub.1 antigen. The resulting erythrocytes may be transfused into individuals who would be otherwise unable to tolerate a transfusion of type A.sub.1 blood.

Endo-.beta.-galactosidase

Growing community of inventors

New York, NY, United States of America

Lin Leng